DOACs reduce cerebrovascular ischemic outcomes and lower bleeding risk compared to vitamin K antagonists in patients with non-valvular atrial fibrillation, with comparable mortality.
Do Direct Oral Anticoagulants (DOACs) reduce cerebrovascular ischemic outcomes compared to Vitamin K Antagonists in patients with non-valvular atrial fibrillation?
DOACs are superior to VKAs for reducing cerebrovascular ischemic outcomes and bleeding risk in non-valvular AF, supporting their use as first-line therapy.
Absolute Event Rate: 0% vs 0%
In patients with non-valvular AF, DOACs demonstrate superior efficacy in reducing cerebrovascular ischemic outcomes and lower bleeding risk compared to VKAs, with comparable mortality outcomes. These findings support current guidelines recommending DOACs as first-line anticoagulation for stroke prevention in AF.
Nasir et al. (Wed,) reported a other. DOACs reduce cerebrovascular ischemic outcomes and lower bleeding risk compared to vitamin K antagonists in patients with non-valvular atrial fibrillation, with comparable mortality.